Roth Capital Initiates Coverage On Coya Therapeutics with Buy Rating, Announces Price Target of $12
Benzinga Newsdesk 5 months ago
NewsPrice TargetInitiationAnalyst Ratings
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Coya Therapeutics (NASDAQ:COYA) with a Buy rating and announces Price Target of $12.